Ozempic Ad - Search News

Ozempic receives FDA nod for treating chronic kidney disease

Ozempic approved for chronic kidney disease patients

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Another busy

People on MSN · 2d

FDA Approves Ozempic to Treat Kidney Disease

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease.

kffhealthnews · 2d

Ozempic Approved To Treat Chronic Kidney Disease With Type 2 Diabetes

The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the United States.

The Baltimore Sun · 1d

FDA approves Ozempic to help reduce risk of worsening chronic kidney disease

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of

Hosted on MSN · 1d

Ozempic receives FDA nod for treating chronic kidney disease; experts explain how diabetes drug reduces CKD risk

The US Food and Drug Administration (FDA) approval is based on the clinical trials that showed how Ozempic, the diabetes drug, showed a reduced risk of kidney failure. Experts explain how the drug helps.

FiercePharma7d

As Super Bowl nears, TV data show GLP-1 game day ads enjoyed a big year

Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company ...

StamfordAdvocate10d

Ziyad Al-Aly, Washington University in St. Louis (THE CONVERSATION) Several years ago, a little-known drug named Ozempic – previously used only to treat diabetes – emerged as a promising new drug ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Ozempic receives FDA nod for treating chronic kidney disease

Trending now